Rablet-B Inventia drug treatment due to gastroesophageal reflux syndrome, esophagus (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Rabeprazole

Ingredient

Composition information	Content
Rabeprazole	20mg

Uses

indications

Rabllet-B medicine indicated for treatment in the following cases:

Treatment of ulcerative ulcerative ulcerative gastroesophageal syndrome (GERD): Rabeprazole is indicated for short -term treatment (from 4 - 8 weeks) to heal and reduce symptoms of ulcerative gastroesophageal and esophagus.

Treatment of sustaining ulcerative ulcerative gastroesophageal disease (GEPD): Rabeprazole is indicated for maintenance treatment to help heal and reduce the recurrence of burning symptoms in patients with gastroesophageal and esophagus ulcers.

Treatment of stomach ulcer, duodenum especially in the case of H. Pylori: Rabeprazole is indicated for short -term treatment (for 4 weeks) to heal and reduce symptoms of peptic ulcer. Most patients achieve treatment results within 4 weeks.

Long-term treatment of pathological secretion including Zollinger-Ellison syndrome.

Pharmacokology

rabeprazole belongs to the group of anti -excreted compounds (conductor of benzimidazole inhibits proton pump), has no antihistamine effect at H2 receptor or cholinergic resistance, but prevents gastric acid secretion due to inhibition of H+, K+ ATPase in the cell wall of the gastric cell wall. These enzymes are considered to be proton pumps in the wall cells, so Rabeprazole is considered as an inhibitor of proton pump. Rabeprazole prevents the final stage of gastric acid secretion. In stomach wall cells, Rabeprazole is received an additional proton, accumulated and converted into activated sulfonamide.

Dynamic pharmacokinetics

When taking the dose of 20mg Rabeprazole, the peak of plasma peaks achieved after 2.0 - 5.0 hours. There is no significant accumulation when taking 10mg - 40mg dose for 24 hours, Rabeprazole's pharmacokinetics does not change by high doses.

Selling plasma waste time is 1-2 hours. Rabeprazole was detected in plasma after 1 hour oral by 20mg.

Absolute bioavailability of Rabeprazole capsules is about 52%. 93% Rabeprazole is connected to plasma proteins.

rabeprazole is strongly metabolized, the main metabolic form detected in plasma is thioete and sulphone. No excretory inhibition is not seen in these forms of metabolic. In vitro tests show that Rabeprazole is metabolized mainly through the liver, due to Cytochrome P450 3A (Sulphone form) and 2C19 (Desmethyl Rabeprazole). 90% of the drug excreted in the urine, mainly in the form of Carboxylic acid, glucuronide bonding and mercapturic acid metabolism.

Rabeprazole gives anti -secreting effect within 1 hour after taking the dose of 20mg. The average inhibitory effect of Rabeprazole should calculate the acidity of the stomach within 248% of the maximum level after the single dose. Compared to placebo, Rabeprazole 20mg inhibits acidic excretion due to stimulation by normal meals and peptone meals are 86% and 95%, and increases the percentage of the period of 24 hours and the stomach has pH> 3 from 10% to 65%. This prolonged pharmacological impact compared to the short selling time of the drug (1-2 hours) shows the prolonged inhibition effect on H+, K+ATPASE.

Special cases

Age: Reports in clinical studies on healthy older people show that the value of AUC has nearly doubled and CMAX increased by 60% when compared to the young group. There is no evidence of the accumulation of drugs when used 1 time/day,

Children: There is no pharmacokinetic study of Rabeprazole in children.

Sex and race: Research on weight and shape analysis shows no differences in pharmacokinetics in men and women volunteers.

Kidney disease: There is no significant clinical difference in pharmacokinetics of Rabeprazole among healthy volunteers and patients with hemolysis.

Liver disease: The data reported from clinical trials with single dose shows that the AUC value and the selling time doubled in mild to moderate cirrhosis patients compared to healthy volunteers. There is no information on patients with severe liver failure.

Before taking Rablet-B Inventia drug treatment due to gastroesophageal reflux syndrome, esophagus (3 blisters x 10 tablets)

How to use

Rabllet-B medication.

Dosage

Treatment of ulcerative ulcerative gastroesophageal disease: recommended dose for adults: 20 mg Rabeprazole/day for 4 - 8 weeks.

Treatment of sustaining ulcers caused by gastroesophageal reflux disease: 20 Rabeprazole/day.

H.pylori except: H.pylori -infected patients should be treated with an exorcic therapy.

Seven -day combination treatments are proposed as follows: Rabeprazole 20 mg twice daily + Clarithromycin 500 mg twice daily and amoxicillin 1g twice daily.

Treatment of disease secretion, including Zollinger-Elison syndrome: The recommended starting dose for adults is 60mg/time/day. Dosage can be adjusted depending on the needs of each patient and may be up to 120mg/day. The dose of 100mg/day can be used once a day. The dose of 120mg/day should be divided into two doses, each dose 60mg. Can be used continuously for a period depending on the requirements of treatment.

No dose adjustments in patients with liver impairment.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when overdose? There is no poison antagonist. Rabeprazole is strongly connected to plasma proteins so it cannot be fertilized. In case of overdose, supportive treatment and symptoms.

In an emergency, call the 115 emergency center immediately or go to the nearest local health station.

What to do when you forget 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.

Side Effects

When using the drug, there are common unwanted effects (ADR) such as:

generally the drug is well tolerated in clinical trials. Unwanted effects are often fleeting and light or medium. The most common side effects are headache, diarrhea and vomiting. The side effects are recorded more than the individual cases listed below by the system group and frequency.

The frequency is defined as follows: Common (> 1/100, 1/10,000,

Common system of systemic agencies Example of swelling, hypotension and shortness of breath) Feeling

Chest respiratory disorders and mediastinum cough, sore throat, rhinitis bronchitis, sinusitis

Burious gastritis, stomatitis, taste disorders Melting, vomiting, nausea, abdominal pain, constipation, flatulence indigestion, dry mouth, belching Gastritis, stomatitis, taste disorders

Skin disorders and subcutaneous tissue Bone

Non -specific pain (back pain) muscle pain, bumping legs, joint pain

general disorders and status at the position of drug use weakness, influenza syndrome chest pain, chills, fever

Scales In the treatment of patients with severe liver dysfunction, doctors are carefully advised to start treatment with pariets in this group.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Rabllet-B anti-contraindications in the following cases:

Contraindicated in patients with hypersensitivity to rabeprazole, benzimidazole derivatives or any ingredients of the drug.

Caution when using

improving symptoms through Rabeprazole treatment does not rule out the presence of bowel cancer or esophageal cancer, so it is necessary to eliminate the possibility of cancer before using the drug.

Patients with long -term treatment (special treatment for more than a year) need to be checked regularly.

In a study in patients with mild liver function impairment to the average of normal and equivalent groups and gender, there is no significant evidence of safety related to using abeprazole. However, there is no clinical data on the use of rabeprazole for patients with severe liver failure, which should be cautious when starting treatment in this target group.

Use for children:

The effects and safety levels of drugs in children have not been determined.

Used for the elderly:

There is no difference in safety and effectiveness between older patients and young people.

Using drugs for women during pregnancy and lactation

Pregnancy:

There are no complete studies on pregnant women. Animal studies can not help predict accurately in humans, so only use this drug for pregnant women when really necessary.

Breastfeeding period:

Because many drugs are excreted through breast milk and there are many risks of side effects on Rabeprazone emulsion, it is necessary to decide to stop using the drug or stop breastfeeding depending on the importance of the drug for the mother.

The effect of the drug on the ability to drive and operate machinery

unknown effects of the drug.

Drug interaction

Rabeprazole is metabolized through the cytochrome P450 (CYP450) enzyme system. Research on a healthy vow shows that Rabeprazole has no significant medium to make other drugs transformed through the CYP450 system such as Warfarin Theophylline oral and Diazepam and Phenytoin using intravenously (use for oral supplements).

Rabeprazole gives prolonged excretion of gastric acid excretion, so it can occur interactive with drugs where the level of absorption is in the stomach. Ketoconazole's bioavailability decreased by 30%), AUC and Digoxin's maximum maximum plasma plasma concentrations increased by 19%and 29%, when used simultaneously with Rabeprazole 20 mg/day. Therefore, the patient needs to be monitored when using the same rabeprazole with these drugs.

Simultaneous use Rabeprazole and antacids do not change the rabepzzole level in plasma.

There is a report that the Inr and prothrombin time in patients taken simultaneously and pumped proton pumps, including Rabeprazole and Warfarin. Inranger increase and prothrombin time can cause abnormal bleeding and can lead to death.

Storage

Leave a cool place, avoid light, temperature below 30⁰C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.